|
See related Tygacil infusion information |
|
|
|
Manufacturer |
Pfizer |
|
Distributor |
Zuellig |
|
Contents |
Tigecycline |
|
Indications |
Treatment of complicated skin & skin structure infections, complicated intra-abdominal infections & community-acquired pneumonia caused by susceptible strains of microorganisms in patients ≥18 yr.
Click to view Tygacil detailed prescribing infomation |
|
Dosage |
Initially 100 mg followed by 50 mg 12 hrly by IV infusion over approx 30-60 min. Duration of treatment: 5-14 days (complicated skin & skin structure infections) or 7-14 days (community-acquired pneumonia). Patients w/ severe hepatic impairment (Child-Pugh C) 100 mg followed by 25 mg 12 hrly.
Click to view Tygacil detailed prescribing infomation |
|
Overdosage |
View Tygacil overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Hypersensitivity.
Click to view Tygacil detailed prescribing infomation |
|
Warnings |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Tygacil detailed prescribing infomation |
|
Special Precautions |
Hypersensitivity to tetracycline class antibiotics. Anaphylaxis/anaphylactoid reactions, pseudomembranous colitis, may cause permanent tooth discoloration, complicated intra-abdominal infections secondary to clinically apparent intestinal perforation, hepatic dysfunction/failure, photosensitivity, pseudotumor cerebri, anti-anabolic action, pancreatitis, hospital-acquired pneumonia, overgrowth of nonsusceptible organisms may occur. May impair ability to drive or operate machinery. Patient <18 yr. Pregnancy & lactation.
Click to view Tygacil detailed prescribing infomation |
|
Adverse Drug Reactions |
GI disturbances, prolonged prothrombin time & activated partial thromboplastin time, bilirubinemia, increased BUN, hypoproteinemia, hypoglycemia, dizziness, phlebitis, pneumonia, anorexia, elevated AST, ALT & serum amylase, pruritus, rash, headache, abnormal healing.
View ADR Monitoring Form |
|
Drug Interactions |
Monitor prothrombin time when given w/ warfarin. May decrease effect of OC.
View more drug interactions with Tygacil |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Tygacil detailed prescribing infomation |
|
Storage |
View Tygacil storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Tygacil description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Tygacil mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Tygacil infusion |
|
Tygacil 50 mg x 1 x 10's |
 |
|
|
|
Manufacturer: |
Pfizer |
|
Distributor: |
Zuellig |
|
 |
|
|
